NOTV

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2007, for Bioanalytical Systems, Inc. (Note: The input metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc., or BASi). The company operates in two segments: Services (contract research and development support for pharmaceutical companies) and Products (scientific instruments for medical research). The company is a non-accelerated filer with 4,909,127 common shares outstanding as of April 30, 2007.

Key Financial Metrics

Note: Debt figures include $4.8 million in current portion of long-term debt and $8.0 million in long-term debt. Subordinated debt of $4.5 million was reclassified to current liabilities due to maturity in Jan 2008.

Material Changes vs. Prior Period

• Revenue Decline (Q/Q): Total revenue decreased 9% to $11.3 million in the quarter compared to $12.4 million in the prior year quarter. Service revenue dropped 13% due to the absence of a large rescheduled study from the prior year, though toxicology and Baltimore clinic revenues increased.
• Revenue Stability (YTD): Six-month revenue remained relatively flat at $22.2 million versus $22.3 million in the prior year. A $1.4 million loss in Baltimore clinical research revenue was offset by gains in U.K., Oregon, and toxicology operations.
• Margin Compression: Gross margin declined from 39.7% to 28.1% in the quarter. This was driven by fixed costs (personnel, facilities) not decreasing proportionally with revenue, and under-absorption of manufacturing costs in the Products segment.
• Expense Reduction: General and administrative expenses decreased 35% in the quarter and 39% year-to-date, attributed to strategic personnel reductions in late 2006 and a shift to temporary staffing in the Baltimore clinic.
• Profitability: The company returned to profitability for the six-month period ($0.7 million net income) compared to a net loss of $0.2 million in the prior year period.

Outlook, Risks, and Contingencies

• Liquidity and Debt Maturity: The company faces a significant liquidity event with $4.0 million of convertible subordinated debt due on January 1, 2008. Management is exploring refinancing options, including mortgage debt, term extensions, or private placements. The debt is subordinated to bank debt and cannot be repaid without senior lender consent.
• Credit Facility: The company maintains a $6.0 million revolving credit agreement expiring December 31, 2007. Approximately $4.0 million was available as of March 31, 2007, reduced by a $1.0 million letter of credit for the Baltimore facility lease.
• Capital Expenditures: Total capital additions for fiscal 2007 are expected to range between $1.0 million and $1.2 million, funded by operating cash flow.
• Market Risks: The business is highly dependent on pharmaceutical industry R&D spending. The company is exposed to interest rate fluctuations on its variable-rate credit facility and foreign currency exchange rates (approx. 26% of cash held in the U.K.), though management estimates a 10% adverse change would not be material.
• Unusual Items: The company recorded a $98,000 loss on the sale of an excess building in West Lafayette, IN, which was held for resale.

Investor Verification Checklist

• Debt Refinancing: Verify the status of refinancing the $4.0 million subordinated debt due in January 2008.
• Service Revenue Volatility: Assess the sustainability of Service segment revenue given the reliance on large, discrete studies (e.g., the rescheduled study impact).
• Margin Recovery: Monitor if gross margins can recover as revenue volumes increase to better absorb fixed costs.
• Credit Facility Renewal: Confirm the extension of the $6.0 million revolving credit facility expiring in December 2007.
• Baltimore Clinic Utilization: Review the performance and cost structure of the Baltimore clinic, which recently lost a significant customer.